Payment overview · 2025
General Payments
$253.12
17 reported records · 4 companies
Healthcare provider profile · identity verified
Lara Cornelia Thibodeaux, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FRANKLIN, TX · NPI 1902894595
Verified facts
What the public records show
CMS Open Payments records show Lara Cornelia Thibodeaux, NP received $253.12 in general payments during 2025 across 17 reported records.
Novo Nordisk Inc accounted for 63.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $159.36 | 63.0% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.46 | 16.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.49 | 14.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.81 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $253.12 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $142.31 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $115.76 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 431 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 368 | 94 |
| Losartan Potassium | Losartan Potassium | 367 | 87 |
| Gabapentin | Gabapentin | 325 | 57 |
| Lisinopril | Lisinopril | 284 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 64 |
| Furosemide | Furosemide | 252 | 53 |
| Potassium Chloride | Potassium Chloride | 189 | 39 |
| Metformin Hcl | Metformin Hcl | 188 | 42 |
| Tramadol Hcl | Tramadol Hcl | 185 | 31 |
| Trazodone Hcl | Trazodone Hcl | 185 | 38 |
| Carvedilol | Carvedilol | 163 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 43 |
| Simvastatin | Simvastatin | 138 | 31 |
| Prednisone | Prednisone | 137 | 96 |
| Januvia | Sitagliptin Phosphate | 135 | 26 |
| Sertraline Hcl | Sertraline Hcl | 126 | 29 |
| Clonazepam | Clonazepam | 111 | 13 |
| Eliquis | Apixaban | 110 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 108 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 26 |
| Donepezil Hcl | Donepezil Hcl | 90 | 18 |
| Jardiance | Empagliflozin | 90 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 25 |
| Alprazolam | Alprazolam | 88 | 16 |
| Meloxicam | Meloxicam | 85 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 41 |
| Celecoxib | Celecoxib | 80 | 20 |
| Cephalexin | Cephalexin | 80 | 58 |
| Omeprazole | Omeprazole | 78 | 23 |
| Spironolactone | Spironolactone | 78 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 27 |
| Montelukast Sodium | Montelukast Sodium | 77 | 19 |
| Azithromycin | Azithromycin | 76 | 66 |
| Clonidine Hcl | Clonidine Hcl | 73 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 23 |
| Divalproex Sodium | Divalproex Sodium | 68 | suppressed |
| Nifedipine Er | Nifedipine | 68 | 12 |
| Glipizide | Glipizide | 63 | 20 |
| Allopurinol | Allopurinol | 61 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 17 |
| Metformin Hcl Er | Metformin Hcl | 60 | 16 |
| Buspirone Hcl | Buspirone Hcl | 56 | suppressed |
| Gemtesa | Vibegron | 54 | suppressed |
| Ozempic | Semaglutide | 51 | suppressed |
| Lorazepam | Lorazepam | 49 | 13 |
| Glyburide | Glyburide | 48 | 12 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 33 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 43 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 12 |
| Glimepiride | Glimepiride | 40 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 16 |
| Ezetimibe | Ezetimibe | 37 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 26 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 20 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Novolin R | Insulin Regular, Human | 22 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 15 |
| Baclofen | Baclofen | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 12 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Tobramycin | Tobramycin | 13 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $253.12 · 17 records | Novo Nordisk Inc | Cologuard Collection Kit, MOUNJARO, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, WaveWriter Alpha Prime 16, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error